<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T02:18:46Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:9071486" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:9071486</identifier>
        <datestamp>2022-05-06</datestamp>
        <setSpec>ehjcvp</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="letter">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Eur Heart J Cardiovasc Pharmacother</journal-id>
              <journal-id journal-id-type="iso-abbrev">Eur Heart J Cardiovasc Pharmacother</journal-id>
              <journal-id journal-id-type="publisher-id">ehjcvp</journal-id>
              <journal-title-group>
                <journal-title>European Heart Journal — Cardiovascular Pharmacotherapy</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">2055-6837</issn>
              <issn pub-type="epub">2055-6845</issn>
              <publisher>
                <publisher-name>Oxford University Press</publisher-name>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC9071486</article-id>
              <article-id pub-id-type="pmcid">PMC9071486</article-id>
              <article-id pub-id-type="pmc-uid">9071486</article-id>
              <article-id pub-id-type="pmid">34902012</article-id>
              <article-id pub-id-type="doi">10.1093/ehjcvp/pvab085</article-id>
              <article-id pub-id-type="publisher-id">pvab085</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Correspondence</subject>
                </subj-group>
                <subj-group subj-group-type="category-taxonomy-collection">
                  <subject>AcademicSubjects/MED00200</subject>
                  <subject>AcademicSubjects/MED00410</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Intensive blood pressure control in patients with a history of heart failure: the Systolic Blood Pressure Intervention Trial (SPRINT)</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0867-5825</contrib-id>
                  <name>
                    <surname>Pareek</surname>
                    <given-names>Manan</given-names>
                  </name>
                  <!--dlbhattmd@post.harvard.edu-->
                  <aff><institution>Heart &amp; Vascular Center, Brigham and Women's Hospital, Harvard Medical School</institution>, 75 Francis St., Boston, MA 02115, <country country="US">USA</country></aff>
                  <aff><institution>Department of Internal Medicine, Yale New Haven Hospital, Yale School of Medicine</institution>, New Haven, CT, <country country="US">USA</country></aff>
                  <aff><institution>Department of Cardiology, Herlev and Gentofte Hospital</institution>, Copenhagen, <country country="DK">Denmark</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-0885-1953</contrib-id>
                  <name>
                    <surname>Vaduganathan</surname>
                    <given-names>Muthiah</given-names>
                  </name>
                  <aff><institution>Heart &amp; Vascular Center, Brigham and Women's Hospital, Harvard Medical School</institution>, 75 Francis St., Boston, MA 02115, <country country="US">USA</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Byrne</surname>
                    <given-names>Christina</given-names>
                  </name>
                  <aff><institution>Department of Cardiology, Herlev and Gentofte Hospital</institution>, Copenhagen, <country country="DK">Denmark</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Mikkelsen</surname>
                    <given-names>Astrid Duus</given-names>
                  </name>
                  <aff><institution>Department of Cardiology</institution>, Bispebjerg and Frederiksberg Hospital, Copenhagen, <country country="DK">Denmark</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Kristensen</surname>
                    <given-names>Anna Meta Dyrvig</given-names>
                  </name>
                  <aff><institution>Department of Cardiology</institution>, Bispebjerg and Frederiksberg Hospital, Copenhagen, <country country="DK">Denmark</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-4209-2778</contrib-id>
                  <name>
                    <surname>Biering-Sørensen</surname>
                    <given-names>Tor</given-names>
                  </name>
                  <aff><institution>Department of Cardiology, Herlev and Gentofte Hospital</institution>, Copenhagen, <country country="DK">Denmark</country></aff>
                  <aff><institution>Institute of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen</institution>, Copenhagen, <country country="DK">Denmark</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Kragholm</surname>
                    <given-names>Kristian Hay</given-names>
                  </name>
                  <aff><institution>Department of Cardiology, Aalborg University Hospital</institution>, Aalborg, <country country="DK">Denmark</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Omar</surname>
                    <given-names>Massar</given-names>
                  </name>
                  <aff><institution>Department of Cardiology, Odense University Hospital</institution>, Odense, <country country="DK">Denmark</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Olsen</surname>
                    <given-names>Michael Hecht</given-names>
                  </name>
                  <aff><institution>Division of Cardiology, Department of Internal Medicine</institution>, Holbæk Hospital, Holbæk, <country country="DK">Denmark</country></aff>
                </contrib>
                <contrib contrib-type="author" corresp="yes">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-0487-7531</contrib-id>
                  <name>
                    <surname>Bhatt</surname>
                    <given-names>Deepak L</given-names>
                  </name>
                  <!--dlbhattmd@post.harvard.edu-->
                  <aff><institution>Heart &amp; Vascular Center, Brigham and Women's Hospital, Harvard Medical School</institution>, 75 Francis St., Boston, MA 02115, <country country="US">USA</country></aff>
                  <xref rid="cor1" ref-type="corresp"/>
                </contrib>
              </contrib-group>
              <author-notes>
                <corresp id="cor1">Corresponding author. Tel: +1 857 307 4071, Fax: +1 857 307 1955, Email: <email>dlbhattmd@post.harvard.edu</email></corresp>
              </author-notes>
              <pub-date pub-type="collection">
                <month>5</month>
                <year>2022</year>
              </pub-date>
              <pub-date pub-type="epub" iso-8601-date="2021-12-13">
                <day>13</day>
                <month>12</month>
                <year>2021</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>13</day>
                <month>12</month>
                <year>2021</year>
              </pub-date>
              <volume>8</volume>
              <issue>3</issue>
              <fpage>E12</fpage>
              <lpage>E14</lpage>
              <history>
                <date date-type="received">
                  <day>21</day>
                  <month>10</month>
                  <year>2021</year>
                </date>
                <date date-type="rev-recd">
                  <day>20</day>
                  <month>11</month>
                  <year>2021</year>
                </date>
                <date date-type="accepted">
                  <day>10</day>
                  <month>12</month>
                  <year>2021</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology.</copyright-statement>
                <copyright-year>2021</copyright-year>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref>
                  <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">https://creativecommons.org/licenses/by-nc/4.0/</ext-link>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact <email>journals.permissions@oup.com</email></license-p>
                </license>
              </permissions>
              <self-uri xlink:href="pvab085.pdf"/>
              <funding-group>
                <award-group award-type="grant">
                  <funding-source>
                    <institution-wrap>
                      <institution>National Heart, Lung, and Blood Institute</institution>
                      <institution-id institution-id-type="DOI">10.13039/100000050</institution-id>
                    </institution-wrap>
                  </funding-source>
                </award-group>
              </funding-group>
              <counts>
                <page-count count="3"/>
              </counts>
            </article-meta>
          </front>
          <body>
            <p>The Systolic Blood Pressure Intervention Trial (SPRINT) found that intensive versus standard blood pressure (BP) control reduced cardiovascular morbidity and mortality in high-risk patients.<sup><xref rid="bib1" ref-type="bibr">1</xref></sup> Effects were consistent among patients with and without prevalent cardiovascular disease. Patients with heart failure may benefit from intensive BP control by slowing the adverse cardiac remodelling associated with high BP. Conversely, some studies have suggested better outcomes among patients with heart failure who have higher BP.<sup><xref rid="bib2" ref-type="bibr">2</xref></sup> Therefore, it remains unknown whether a history of heart failure modifies the risks and benefits of intensive BP control.</p>
            <p>SPRINT randomized 9361 individuals who were ≥50 years of age, at high cardiovascular risk, and had a systolic BP of 130–180 mmHg to intensive or standard BP control.<sup><xref rid="bib1" ref-type="bibr">1</xref></sup> Pertinent exclusion criteria included diabetes, prior stroke, and known symptomatic heart failure within the past 6 months or a left ventricular ejection fraction &lt;35%. The primary endpoint was the composite of acute coronary syndromes, stroke, acute decompensated heart failure, or death from cardiovascular causes. The principal safety endpoint was composite serious adverse events. We used multivariable Cox proportional hazards regression to determine the risk of efficacy and safety events in patients with baseline heart failure. We then calculated the efficacy and safety of intensive versus standard BP control in patients with and without baseline heart failure and examined subgroup heterogeneity using the likelihood-ratio test. A waiver for secondary use of the SPRINT data set was obtained from the Brigham and Women's Hospital Institutional Review Board.</p>
            <p>Of the 9361 participants, 326 (3.5%) reported a history of heart failure. The prevalence did not significantly differ between patients randomized to intensive versus standard BP control [166 (3.6%) vs. 160 (3.4%); <italic toggle="yes">P</italic> = 0.73]. Median follow-up duration was 3.26 years (range 0–4.77 years). A history of heart failure was independently associated with</p>
            <p>the primary endpoint (adjusted hazard ratio: 2.34; 95% confidence interval: 1.75–3.13; <italic toggle="yes">P</italic> &lt; 0.001) and with composite serious adverse events (adjusted hazard ratio: 1.41; 95% confidence interval: 1.21-1.64; <italic toggle="yes">P</italic> &lt; 0.001). No significant interactions were detected for any of the endpoints (<xref rid="tbl1" ref-type="table"><italic toggle="yes">Table 1</italic></xref>). Patients with a history of heart failure had higher risks and greater absolute risk reductions in several efficacy endpoints, including the primary endpoint and all-cause death. The risk of safety endpoints was also higher in patients with heart failure, but mostly similar between the intensive and standard groups (<xref rid="tbl1" ref-type="table"><italic toggle="yes">Table 1</italic></xref>).</p>
            <table-wrap position="float" id="tbl1">
              <label>Table 1</label>
              <caption>
                <p>Efficacy and safety events with intensive vs. standard blood pressure control in patients with and without heart failure</p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th rowspan="1" colspan="1"/>
                    <th align="center" colspan="3" rowspan="1">Patients with heart failure (<italic toggle="yes">n</italic> = 326)</th>
                    <th align="center" colspan="3" rowspan="1">Patients without heart failure (<italic toggle="yes">n</italic> = 9035)</th>
                    <th rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <th align="left" rowspan="1" colspan="1">Endpoint</th>
                    <th align="left" rowspan="1" colspan="1">Intensive BP control [no. of patients (%)]</th>
                    <th align="left" rowspan="1" colspan="1">Standard BP control [no. of patients (%)]</th>
                    <th align="left" rowspan="1" colspan="1">Hazard ratio (95% confidence interval)</th>
                    <th align="left" rowspan="1" colspan="1">Intensive BP control [no. of patients (%)]</th>
                    <th align="left" rowspan="1" colspan="1">Standard BP control [no. of patients (%)]</th>
                    <th align="left" rowspan="1" colspan="1">Hazard ratio (95% confidence interval)</th>
                    <th align="left" rowspan="1" colspan="1"><italic toggle="yes">P</italic>-value for interaction</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td rowspan="1" colspan="1">All participants</td>
                    <td rowspan="1" colspan="1">166</td>
                    <td rowspan="1" colspan="1">160</td>
                    <td rowspan="1" colspan="1"/>
                    <td rowspan="1" colspan="1">4512</td>
                    <td rowspan="1" colspan="1">4523</td>
                    <td rowspan="1" colspan="1"/>
                    <td rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td rowspan="1" colspan="1">Primary endpoint</td>
                    <td rowspan="1" colspan="1">22 (13.3%)</td>
                    <td rowspan="1" colspan="1">34 (21.3%)</td>
                    <td rowspan="1" colspan="1">0.58 (0.34–0.99)</td>
                    <td rowspan="1" colspan="1">221 (4.9%)</td>
                    <td rowspan="1" colspan="1">285 (6.3%)</td>
                    <td rowspan="1" colspan="1">0.77 (0.65–0.92)</td>
                    <td rowspan="1" colspan="1">0.33</td>
                  </tr>
                  <tr>
                    <td rowspan="1" colspan="1">Secondary endpoints</td>
                    <td rowspan="1" colspan="1"/>
                    <td rowspan="1" colspan="1"/>
                    <td rowspan="1" colspan="1"/>
                    <td rowspan="1" colspan="1"/>
                    <td rowspan="1" colspan="1"/>
                    <td rowspan="1" colspan="1"/>
                    <td rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td rowspan="1" colspan="1"><italic toggle="yes"> </italic>Myocardial infarction</td>
                    <td rowspan="1" colspan="1">3 (1.8%)</td>
                    <td rowspan="1" colspan="1">8 (5.0%)</td>
                    <td rowspan="1" colspan="1">0.34 (0.09–1.29)</td>
                    <td rowspan="1" colspan="1">94 (2.1%)</td>
                    <td rowspan="1" colspan="1">108 (2.4%)</td>
                    <td rowspan="1" colspan="1">0.87 (0.66–1.15)</td>
                    <td rowspan="1" colspan="1">0.16</td>
                  </tr>
                  <tr>
                    <td rowspan="1" colspan="1"><italic toggle="yes"> </italic>Other acute coronary syndrome</td>
                    <td rowspan="1" colspan="1">3 (1.8%)</td>
                    <td rowspan="1" colspan="1">5 (3.1%)</td>
                    <td rowspan="1" colspan="1">0.56 (0.13–2.35)</td>
                    <td rowspan="1" colspan="1">37 (0.8%)</td>
                    <td rowspan="1" colspan="1">35 (0.8%)</td>
                    <td rowspan="1" colspan="1">1.06 (0.67–1.68)</td>
                    <td rowspan="1" colspan="1">0.40</td>
                  </tr>
                  <tr>
                    <td rowspan="1" colspan="1"><italic toggle="yes"> </italic>Stroke</td>
                    <td rowspan="1" colspan="1">6 (3.6%)</td>
                    <td rowspan="1" colspan="1">6 (3.8%)</td>
                    <td rowspan="1" colspan="1">0.92 (0.30–2.85)</td>
                    <td rowspan="1" colspan="1">56 (1.2%)</td>
                    <td rowspan="1" colspan="1">64 (1.4%)</td>
                    <td rowspan="1" colspan="1">0.87 (0.61–1.25)</td>
                    <td rowspan="1" colspan="1">0.92</td>
                  </tr>
                  <tr>
                    <td rowspan="1" colspan="1"><italic toggle="yes"> </italic>Acute decompensated heart failure</td>
                    <td rowspan="1" colspan="1">12 (7.2%)</td>
                    <td rowspan="1" colspan="1">18 (11.3%)</td>
                    <td rowspan="1" colspan="1">0.61 (0.29–1.27)</td>
                    <td rowspan="1" colspan="1">50 (1.1%)</td>
                    <td rowspan="1" colspan="1">82 (1.8%)</td>
                    <td rowspan="1" colspan="1">0.61 (0.43–0.86)</td>
                    <td rowspan="1" colspan="1">&gt;0.99</td>
                  </tr>
                  <tr>
                    <td rowspan="1" colspan="1"><italic toggle="yes"> </italic>Death from cardiovascular causes</td>
                    <td rowspan="1" colspan="1">5 (3.0%)</td>
                    <td rowspan="1" colspan="1">7 (4.4%)</td>
                    <td rowspan="1" colspan="1">0.66 (0.21–2.08)</td>
                    <td rowspan="1" colspan="1">32 (0.7%)</td>
                    <td rowspan="1" colspan="1">58 (1.3%)</td>
                    <td rowspan="1" colspan="1">0.55 (0.36–0.85)</td>
                    <td rowspan="1" colspan="1">0.76</td>
                  </tr>
                  <tr>
                    <td rowspan="1" colspan="1"><italic toggle="yes"> </italic>Death from any cause</td>
                    <td rowspan="1" colspan="1">12 (7.2%)</td>
                    <td rowspan="1" colspan="1">18 (11.3%)</td>
                    <td rowspan="1" colspan="1">0.62 (0.30–1.29)</td>
                    <td rowspan="1" colspan="1">143 (3.2%)</td>
                    <td rowspan="1" colspan="1">192 (4.2%)</td>
                    <td rowspan="1" colspan="1">0.74 (0.60–0.92)</td>
                    <td rowspan="1" colspan="1">0.64</td>
                  </tr>
                  <tr>
                    <td rowspan="1" colspan="1"><italic toggle="yes"> </italic>Primary endpoint with death from any cause</td>
                    <td rowspan="1" colspan="1">26 (15.7%)</td>
                    <td rowspan="1" colspan="1">42 (26.3%)</td>
                    <td rowspan="1" colspan="1">0.55 (0.34–0.90)</td>
                    <td rowspan="1" colspan="1">306 (6.8%)</td>
                    <td rowspan="1" colspan="1">381 (8.4%)</td>
                    <td rowspan="1" colspan="1">0.80 (0.69–0.93)</td>
                    <td rowspan="1" colspan="1">0.17</td>
                  </tr>
                  <tr>
                    <td rowspan="1" colspan="1">Composite serious adverse events</td>
                    <td rowspan="1" colspan="1">97 (58.4%)</td>
                    <td rowspan="1" colspan="1">90 (56.3%)</td>
                    <td rowspan="1" colspan="1">1.01 (0.76–1.35)</td>
                    <td rowspan="1" colspan="1">1696 (37.6%)</td>
                    <td rowspan="1" colspan="1">1646 (36.4%)</td>
                    <td rowspan="1" colspan="1">1.04 (0.97–1.11)</td>
                    <td rowspan="1" colspan="1">0.83</td>
                  </tr>
                  <tr>
                    <td rowspan="1" colspan="1">Emergency department visit or serious adverse events</td>
                    <td rowspan="1" colspan="1"/>
                    <td rowspan="1" colspan="1"/>
                    <td rowspan="1" colspan="1"/>
                    <td rowspan="1" colspan="1"/>
                    <td rowspan="1" colspan="1"/>
                    <td rowspan="1" colspan="1"/>
                    <td rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td rowspan="1" colspan="1"><italic toggle="yes"> </italic>Hypotension</td>
                    <td rowspan="1" colspan="1">13 (7.8%)</td>
                    <td rowspan="1" colspan="1">6 (3.8%)</td>
                    <td rowspan="1" colspan="1">2.07 (0.79–5.44)</td>
                    <td rowspan="1" colspan="1">145 (3.2%)</td>
                    <td rowspan="1" colspan="1">87 (1.9%)</td>
                    <td rowspan="1" colspan="1">1.68 (1.29–2.19)</td>
                    <td rowspan="1" colspan="1">0.71</td>
                  </tr>
                  <tr>
                    <td rowspan="1" colspan="1"><italic toggle="yes"> </italic>Syncope</td>
                    <td rowspan="1" colspan="1">8 (4.8%)</td>
                    <td rowspan="1" colspan="1">7 (4.4%)</td>
                    <td rowspan="1" colspan="1">1.08 (0.39–2.97)</td>
                    <td rowspan="1" colspan="1">155 (3.4%)</td>
                    <td rowspan="1" colspan="1">106 (2.3%)</td>
                    <td rowspan="1" colspan="1">1.47 (1.15–1.88)</td>
                    <td rowspan="1" colspan="1">0.53</td>
                  </tr>
                  <tr>
                    <td rowspan="1" colspan="1"><italic toggle="yes"> </italic>Bradycardia</td>
                    <td rowspan="1" colspan="1">11 (6.6%)</td>
                    <td rowspan="1" colspan="1">8 (5.0%)</td>
                    <td rowspan="1" colspan="1">1.29 (0.52–3.21)</td>
                    <td rowspan="1" colspan="1">93 (2.1%)</td>
                    <td rowspan="1" colspan="1">75 (1.7%)</td>
                    <td rowspan="1" colspan="1">1.24 (0.92–1.68)</td>
                    <td rowspan="1" colspan="1">0.95</td>
                  </tr>
                  <tr>
                    <td rowspan="1" colspan="1"><italic toggle="yes"> </italic>Electrolyte abnormality</td>
                    <td rowspan="1" colspan="1">8 (4.8%)</td>
                    <td rowspan="1" colspan="1">8 (5.0%)</td>
                    <td rowspan="1" colspan="1">0.92 (0.34–2.45)</td>
                    <td rowspan="1" colspan="1">169 (3.8%)</td>
                    <td rowspan="1" colspan="1">121 (2.7%)</td>
                    <td rowspan="1" colspan="1">1.40 (1.11–1.77)</td>
                    <td rowspan="1" colspan="1">0.43</td>
                  </tr>
                  <tr>
                    <td rowspan="1" colspan="1"><italic toggle="yes"> </italic>Injurious fall</td>
                    <td rowspan="1" colspan="1">18 (10.8%)</td>
                    <td rowspan="1" colspan="1">19 (11.9%)</td>
                    <td rowspan="1" colspan="1">0.86 (0.45–1.64)</td>
                    <td rowspan="1" colspan="1">316 (7.0%)</td>
                    <td rowspan="1" colspan="1">313 (6.9%)</td>
                    <td rowspan="1" colspan="1">1.01 (0.86–1.18)</td>
                    <td rowspan="1" colspan="1">0.59</td>
                  </tr>
                  <tr>
                    <td rowspan="1" colspan="1"><italic toggle="yes"> </italic>Acute kidney injury or renal failure</td>
                    <td rowspan="1" colspan="1">18 (10.8%)</td>
                    <td rowspan="1" colspan="1">13 (8.1%)</td>
                    <td rowspan="1" colspan="1">1.30 (0.63–2.64)</td>
                    <td rowspan="1" colspan="1">186 (4.1%)</td>
                    <td rowspan="1" colspan="1">107 (2.4%)</td>
                    <td rowspan="1" colspan="1">1.75 (1.38–2.22)</td>
                    <td rowspan="1" colspan="1">0.41</td>
                  </tr>
                  <tr>
                    <td rowspan="1" colspan="1"><italic toggle="yes"> </italic>Orthostatic hypotension alone</td>
                    <td rowspan="1" colspan="1">40 (24.1%)</td>
                    <td rowspan="1" colspan="1">42 (26.3%)</td>
                    <td rowspan="1" colspan="1">0.74 (0.47–1.41)</td>
                    <td rowspan="1" colspan="1">737 (16.3%)</td>
                    <td rowspan="1" colspan="1">815 (18.0%)</td>
                    <td rowspan="1" colspan="1">0.89 (0.81–0.98)</td>
                    <td rowspan="1" colspan="1">0.37</td>
                  </tr>
                  <tr>
                    <td rowspan="1" colspan="1"><italic toggle="yes"> </italic>Orthostatic hypotension with dizziness</td>
                    <td rowspan="1" colspan="1">4 (2.4%)</td>
                    <td rowspan="1" colspan="1">2 (1.3%)</td>
                    <td rowspan="1" colspan="1">1.87 (0.34–10.21)</td>
                    <td rowspan="1" colspan="1">58 (1.3%)</td>
                    <td rowspan="1" colspan="1">69 (1.5%)</td>
                    <td rowspan="1" colspan="1">0.83 (0.58–1.17)</td>
                    <td rowspan="1" colspan="1">0.50</td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn id="tb1fn1">
                  <p>BP, blood pressure.</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
            <p>Our study showed a greater risk of both efficacy and safety events among individuals with heart failure, but no significant differences in the risk–benefit profile of intensive BP control. Effects were virtually identical in patients with vs. those without heart failure. Nevertheless, data regarding the exact phenotype, disease severity, or functional status of individuals with heart failure were not available. It seems likely that a significant proportion of these patients had heart failure with mildly reduced ejection fraction, heart failure with preserved ejection fraction (HFpEF), or heart failure with recovered ejection fraction, and our data support the class I guideline recommendation to control BP in patients with HFpEF.<sup><xref rid="bib3" ref-type="bibr">3</xref></sup> Other limitations were the small sample size, exclusion of other specific high-risk conditions, and that heart failure was self-reported. In conclusion, a specific subgroup of patients with heart failure faces excess risks of clinical adverse events but appears to benefit from intensive BP control to attenuate this risk. Future prospective clinical trials are needed to establish optimal BP targets in HFpEF.</p>
          </body>
          <back>
            <sec id="sec2">
              <sec id="sec2-1">
                <title>Funding</title>
                <p>SPRINT was supported by the National Heart, Lung, and Blood Institute. This exploratory analysis was unfunded.</p>
                <p><bold>Trial registration number:</bold> NCT01206062</p>
              </sec>
              <sec id="sec3">
                <p><bold>Conflict of interest:</bold> M.P. discloses the following relationships—advisory board: AstraZeneca and Janssen-Cilag; speaker honorarium: AstraZeneca, Bayer, Boehringer Ingelheim, and Janssen-Cilag.</p>
                <p>M.V. has received research grant support or served on advisory boards for American Regent, Amgen, AstraZeneca, Bayer AG, Baxter Healthcare, Boehringer Ingelheim, Cytokinetics, Lexicon Pharmaceuticals, Relypsa, and Roche Diagnostics; had speaker engagements with Novartis and Roche Diagnostics; and participates in clinical endpoint committees for studies sponsored by Galmed and Novartis.</p>
              </sec>
              <sec id="sec4">
                <p>T.B.S. discloses the following relationships—steering committee member of the Amgen-financed GALACTIC-HF trial; advisory board: Sanofi Pasteur and Amgen; and speaker honorarium: Novartis and Sanofi Pasteur.</p>
                <p>M.H.O. discloses that he has received a part-time clinical research grant from the Novo Nordisk Foundation.</p>
                <p>D.L.B. discloses the following relationships—advisory board: Boehringer Ingelheim, Cardax, CellProthera, Cereno Scientific, Elsevier Practice Update Cardiology, Janssen, Level Ex, Medscape Cardiology, MyoKardia, NirvaMed, Novo Nordisk, PhaseBio, PLx Pharma, Regado Biosciences, and Stasys; board of directors: Boston VA Research Institute, Society of Cardiovascular Patient Care, and TobeSoft; chair: inaugural chair, American Heart Association Quality Oversight Committee; data monitoring committees: Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute, for the PORTICO trial, funded by St. Jude Medical, now Abbott), Boston Scientific (chair, PEITHO trial), Cleveland Clinic (including for the ExCEED trial, funded by Edwards), Contego Medical (chair, PERFORMANCE 2), Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine (for the ENVISAGE trial, funded by Daiichi Sankyo), Novartis, and Population Health Research Institute; honoraria: American College of Cardiology (senior associate editor, <italic toggle="yes">Clinical Trials and News</italic>, <ext-link xlink:href="http://www.acc.org" ext-link-type="uri">acc.org</ext-link>; chair, ACC Accreditation Oversight Committee), Arnold and Porter law firm (work related to Sanofi/Bristol-Myers Squibb clopidogrel litigation), Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute; RE-DUAL PCI clinical trial steering committee funded by Boehringer Ingelheim; AEGIS-II executive committee funded by CSL Behring), Belvoir Publications (editor-in-chief, <italic toggle="yes">Harvard Heart Letter</italic>), Canadian Medical and Surgical Knowledge Translation Research Group (clinical trial steering committees), Cowen and Company, Duke Clinical Research Institute (clinical trial steering committees, including for the PRONOUNCE trial, funded by Ferring Pharmaceuticals), HMP Global (editor-in-chief, <italic toggle="yes">Journal of Invasive Cardiology</italic>), <italic toggle="yes">Journal of the American College of Cardiology</italic> (guest editor; associate editor), K2P (co-chair, interdisciplinary curriculum), Level Ex, Medtelligence/ReachMD (CME steering committees), MJH Life Sciences, Piper Sandler, Population Health Research Institute (for the COMPASS operations committee, publications committee, steering committee, and USA national co-leader, funded by Bayer), Slack Publications (chief medical editor, <italic toggle="yes">Cardiology Today's Intervention</italic>), Society of Cardiovascular Patient Care (secretary/treasurer), and WebMD (CME steering committees); others: <italic toggle="yes">Clinical Cardiology</italic> (deputy editor), NCDR-ACTION Registry Steering Committee (chair), and VA CART Research and Publications Committee (chair); research funding: Abbott, Afimmune, Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Cardax, CellProthera, Cereno Scientific, Chiesi, CSL Behring, Eisai, Ethicon, Faraday Pharmaceuticals, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, Garmin, HLS Therapeutics, Idorsia, Ironwood, Ischemix, Janssen, Lexicon, Lilly, Medtronic, MyoKardia, NirvaMed, Novartis, Novo Nordisk, Owkin, Pfizer, PhaseBio, PLx Pharma, Regeneron, Roche, Sanofi, Stasys, Synaptic, The Medicines Company, and 89Bio; royalties: Elsevier (editor, <italic toggle="yes">Cardiovascular Intervention: A Companion to Braunwald's Heart Disease</italic>); site co-investigator: Abbott, Biotronik, Boston Scientific, CSI, St. Jude Medical (now Abbott), Philips, and Svelte; trustee: American College of Cardiology; and unfunded research: FlowCo, Merck, and Takeda.</p>
                <p>The other authors report no conflict of interest.</p>
              </sec>
            </sec>
            <ref-list id="ref1">
              <title>References</title>
              <ref id="bib1">
                <label>1.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>SPRINT Research Group</collab></person-group>, <person-group person-group-type="editor"><string-name><surname>Wright</surname><given-names>JT</given-names><suffix>Jr</suffix></string-name>, <string-name><surname>Williamson</surname><given-names>JD</given-names></string-name>, <string-name><surname>Whelton</surname><given-names>PK</given-names></string-name>, <string-name><surname>Snyder</surname><given-names>JK</given-names></string-name>, <string-name><surname>Sink</surname><given-names>KM</given-names></string-name>, <string-name><surname>Rocco</surname><given-names>MV</given-names></string-name>, <string-name><surname>Reboussin</surname><given-names>DM</given-names></string-name>, <string-name><surname>Rahman</surname><given-names>M</given-names></string-name>, <string-name><surname>Oparil</surname><given-names>S</given-names></string-name>, <string-name><surname>Lewis</surname><given-names>CE</given-names></string-name>, <string-name><surname>Kimmel</surname><given-names>PL</given-names></string-name>, <string-name><surname>Johnson</surname><given-names>KC</given-names></string-name>, <string-name><surname>Goff</surname><given-names>DC</given-names><suffix>Jr</suffix></string-name>, <string-name><surname>Fine</surname><given-names>LJ</given-names></string-name>, <string-name><surname>Cutler</surname><given-names>JA</given-names></string-name>, <string-name><surname>Cushman</surname><given-names>WC</given-names></string-name>, <string-name><surname>Cheung</surname><given-names>AK</given-names></string-name>, <string-name><surname>Ambrosius</surname><given-names>WT</given-names></string-name></person-group>. <article-title>A randomized trial of intensive versus standard blood-pressure control</article-title>. <source>N Engl J Med</source><year>2015</year>;<volume>373</volume>:<fpage>2103</fpage>–<lpage>2116</lpage>.<pub-id pub-id-type="pmid">26551272</pub-id></mixed-citation>
              </ref>
              <ref id="bib2">
                <label>2.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Raphael</surname><given-names>CE</given-names></string-name>, <string-name><surname>Whinnett</surname><given-names>ZI</given-names></string-name>, <string-name><surname>Davies</surname><given-names>JE</given-names></string-name>, <string-name><surname>Fontana</surname><given-names>M</given-names></string-name>, <string-name><surname>Ferenczi</surname><given-names>EA</given-names></string-name>, <string-name><surname>Manisty</surname><given-names>CH</given-names></string-name>, <string-name><surname>Mayet</surname><given-names>J</given-names></string-name>, <string-name><surname>Francis</surname><given-names>DP</given-names></string-name></person-group>. <article-title>Quantifying the paradoxical effect of higher systolic blood pressure on mortality in chronic heart failure</article-title>. <source>Heart</source><year>2009</year>;<volume>95</volume>:<fpage>56</fpage>–<lpage>62</lpage>.<pub-id pub-id-type="pmid">18653573</pub-id></mixed-citation>
              </ref>
              <ref id="bib3">
                <label>3.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yancy</surname><given-names>CW</given-names></string-name>, <string-name><surname>Jessup</surname><given-names>M</given-names></string-name>, <string-name><surname>Bozkurt</surname><given-names>B</given-names></string-name>, <string-name><surname>Butler</surname><given-names>J</given-names></string-name>, <string-name><surname>Casey</surname><given-names>DE</given-names><suffix>Jr</suffix></string-name>, <string-name><surname>Colvin</surname><given-names>MM</given-names></string-name>, <string-name><surname>Drazner</surname><given-names>MH</given-names></string-name>, <string-name><surname>Filippatos</surname><given-names>GS</given-names></string-name>, <string-name><surname>Fonarow</surname><given-names>GC</given-names></string-name>, <string-name><surname>Givertz</surname><given-names>MM</given-names></string-name>, <string-name><surname>Hollenberg</surname><given-names>SM</given-names></string-name>, <string-name><surname>Lindenfeld</surname><given-names>J</given-names></string-name>, <string-name><surname>Masoudi</surname><given-names>FA</given-names></string-name>, <string-name><surname>McBride</surname><given-names>PE</given-names></string-name>, <string-name><surname>Peterson</surname><given-names>PN</given-names></string-name>, <string-name><surname>Stevenson</surname><given-names>LW</given-names></string-name>, <string-name><surname>Westlake</surname><given-names>C</given-names></string-name></person-group>. <article-title>2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America</article-title>. <source>Circulation</source><year>2017</year>;<volume>136</volume>:<fpage>e137</fpage>–<lpage>e161</lpage>.<pub-id pub-id-type="pmid">28455343</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
